Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans

[1]  B. Ring,et al.  The human drug metabolizing cytochromes P450 , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  F. Guengerich,et al.  In Vitro techniques for studying drug metabolism , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[4]  F. Aweeka,et al.  The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy , 1996, Clinical pharmacokinetics.

[5]  M Rowland,et al.  Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.

[6]  A. Renwick,et al.  Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. , 1995, British journal of clinical pharmacology.

[7]  S. Krähenbühl,et al.  Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.

[8]  A. Guillouzo,et al.  Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Held at Utrecht, The Netherlands, 6-8 September 1994. , 1995 .

[9]  M. Ducharme,et al.  Disposition of intravenous and oral cyclosporine after administration with grapefruit juice , 1995, Clinical pharmacology and therapeutics.

[10]  A. D. Rodrigues,et al.  Use of in vitro human metabolism studies in drug development. An industrial perspective. , 1994, Biochemical pharmacology.

[11]  P. Watkins.  Noninvasive tests of CYP3A enzymes. , 1994, Pharmacogenetics.

[12]  D. Bailey,et al.  Grapefruit Juice and Drugs , 1994, Clinical pharmacokinetics.

[13]  D. Wortham,et al.  Itraconazole Affects Single‐Dose Terfenadine Pharmacokinetics and Cardiac Repolarization Pharmacodynamics , 1993, Journal of clinical pharmacology.

[14]  D. Wortham,et al.  The effect of fluconazole on the steady‐state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans , 1993, Clinical pharmacology and therapeutics.

[15]  R Temple,et al.  Understanding consequences of concurrent therapies. , 1993, JAMA.

[16]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[17]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[18]  F. Flores-Murrieta,et al.  Pharmacokinetics of Oral Nifedipine in Different Populations , 1993, Journal of clinical pharmacology.

[19]  R. Woosley,et al.  Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.

[20]  E. Schuetz,et al.  Expression of cytochrome P450 3A in amphibian, rat, and human kidney. , 1992, Archives of biochemistry and biophysics.

[21]  C. L. Ferguson,et al.  Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.

[22]  G. Yee,et al.  Pharmacokinetic Drug Interactions with Cyclosporin (Part II) , 1990, Clinical pharmacokinetics.

[23]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[25]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[26]  D. Weiner,et al.  Bioavailability of terfenadine in man. , 1981, Biopharmaceutics & drug disposition.

[27]  K. Detering,et al.  Letter: Anti-epileptic drugs and failure of oral contraceptives. , 1974, Lancet.

[28]  D. Reimers,et al.  [The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives]. , 1971, Praxis der Pneumologie.

[29]  M. Viitasalo,et al.  Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia , 2004, European Journal of Clinical Pharmacology.

[30]  D. Wortham,et al.  Comparison of the Effect of the Macrolide Antibiotics Erythromycin, Clarithromycin and Azithromycin on Terfenadine Steady-State Pharmacokinetics and Electrocardiographic Parameters , 1994 .

[31]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[32]  David W. Warnock,et al.  Clinical Pharmacokinetics of Ketoconazole , 1988, Clinical pharmacokinetics.

[33]  R. Hook,et al.  Pharmacokinetics and biotransformation studies of terfenadine in man. , 1982, Arzneimittel-Forschung.